NDASUBLINGUALTABLET
Approved
Mar 2009
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
3
Data completeness
7/8 — Comprehensive
EDLUAR (zolpidem tartrate) by Viatris (2) is short-term treatment of insomnia through binding to the benzodiazepine site of α 1 subunit containing gaba a receptors, increasing the frequency of chloride channel opening resulting in the inhibition of neuronal excitation. Approved for insomnia. First approved in 2009.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EDLUAR is a sublingual tablet formulation of zolpidem tartrate approved in 2009 for short-term insomnia treatment. It works by binding to benzodiazepine receptors on GABA-A channels, increasing chloride channel opening frequency and inhibiting neuronal excitation to promote sleep onset.
$0.749MPart D
Peak4.8 years to LOEProduct is in peak lifecycle phase with modest Part D spending (1,190 claims in 2023), indicating stable but niche market positioning suitable for specialized commercial teams.
Mechanism of Action
short-term treatment of insomnia through binding to the benzodiazepine site of α 1 subunit containing GABA A receptors, increasing the frequency of chloride channel opening resulting in the inhibition of neuronal excitation.
Indications (1)
Clinical Trials (3)
Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo
Started Jan 2006
36 enrolled
Insomnia
Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions
Started Mar 2002
24 enrolled
Healthy
Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions
Started Feb 2002
38 enrolled
Healthy
Worked on EDLUAR at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.